Drug Trial Radar · NCT07402330
Pharmacokinetic Study of DA-020
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 16, 2026
Primary completion
Oct 19, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Applied Biology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Daniel Alain, Inc.; Follea International Limited
- First posted
- Feb 11, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Pharmacokinetic Study of DA-020
Conditions
- Chemotherapy Induced Alopecia
- Chemotherapy Side Effects
Interventions
DA-020 (0.1%)Drug
DA-020 (0.1%)
DA-020 (0.2%)Drug
DA-020 (0.2%)
DA-020 (0.5%)Drug
DA-020 (0.5%)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of DA-020 in SerumTime frame: Hours [0, 1, 2, 4, 8, 12, 24]
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Hospital Samel
Manaus, Brazil
University of Rome ("G. Marconi")
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.